<< Back | Compounding News Home
Protect your Access to Bioidentical Hormones

The FDA commissioned a study from the National Academies of Sciences, Engineering, and Medicine on the safety, effectiveness, and use of compounded bioidentical hormone therapy (cBHT or cBHRT). The NASEM committee has suggested restricting use of cBHT to patients with allergies to FDA-approved drugs, despite the fact that many FDA-approved therapies may not meet the dosing needs of all patients. The committee did not include a pharmacist with clinical experience, a compounding pharmacist, or a physician with substantive experience in bioidentical hormone therapy. For decades, pharmacists around the world have safely compounded specific strengths and dosage forms of hormones using the highest quality ingredients (identical to those used in manufacturing FDA-approved products). Ask our pharmacist how to protect your access to compounded hormone therapies. “Join” us at https://www.p3rx.org for updates.



Copyright © 2007 - 2021, Storey Marketing. All rights reserved.